Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Jun;36(6):1208–1214. doi: 10.1128/aac.36.6.1208

Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin.

H Anwar 1, J L Strap 1, K Chen 1, J W Costerton 1
PMCID: PMC190319  PMID: 1416820

Abstract

The dynamic interaction of planktonic and biofilm cells of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin was investigated in a chemostat system. The results indicated that planktonic and young biofilm cells of the 2-day-old chemostat culture of P. aeruginosa were susceptible to killing by chemostat-controlled doses of either 250 micrograms of piperacillin per ml plus 5 micrograms of tobramycin per ml or 500 micrograms of piperacillin per ml plus 5 micrograms of tobramycin per ml. Complete eradication of the planktonic and young biofilm cells was observed after exposure of the cells to six chemostat-controlled doses of these antibiotic at 8-h intervals for 7 days. Regrowth of the organism was not observed after the termination of antibiotic therapy on day 7. A different picture was observed when antibiotic treatment was initiated on day 10 after inoculation. Viable old biofilm cells were reduced to approximately 20% after exposure to the chemostat-controlled doses of 500 micrograms of piperacillin per ml plus 5 micrograms of tobramycin per ml. Complete eradication of old biofilm cells could not be achieved, and regrowth of the organism occurred after the termination of antibiotic therapy. These data suggest that young biofilm cells of mucoid P. aeruginosa can be effectively eradicated with the combination of piperacillin and tobramycin, while old biofilm cells are very resistant to these antibiotics and eradication of old biofilm cells is not achievable with the chemostat-controlled doses of piperacillin and tobramycin used in this study.

Full text

PDF
1208

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anwar H., Costerton J. W. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Sep;34(9):1666–1671. doi: 10.1128/aac.34.9.1666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anwar H., Dasgupta M. K., Costerton J. W. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother. 1990 Nov;34(11):2043–2046. doi: 10.1128/aac.34.11.2043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anwar H., Dasgupta M., Lam K., Costerton J. W. Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation. J Antimicrob Chemother. 1989 Nov;24(5):647–655. doi: 10.1093/jac/24.5.647. [DOI] [PubMed] [Google Scholar]
  4. Anwar H., van Biesen T., Dasgupta M., Lam K., Costerton J. W. Interaction of biofilm bacteria with antibiotics in a novel in vitro chemostat system. Antimicrob Agents Chemother. 1989 Oct;33(10):1824–1826. doi: 10.1128/aac.33.10.1824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Costerton J. W., Cheng K. J., Geesey G. G., Ladd T. I., Nickel J. C., Dasgupta M., Marrie T. J. Bacterial biofilms in nature and disease. Annu Rev Microbiol. 1987;41:435–464. doi: 10.1146/annurev.mi.41.100187.002251. [DOI] [PubMed] [Google Scholar]
  6. Costerton J. W., Lam J., Lam K., Chan R. The role of the microcolony mode of growth in the pathogenesis of Pseudomonas aeruginosa infections. Rev Infect Dis. 1983 Nov-Dec;5 (Suppl 5):S867–S873. doi: 10.1093/clinids/5.supplement_5.s867. [DOI] [PubMed] [Google Scholar]
  7. Giwercman B., Jensen E. T., Høiby N., Kharazmi A., Costerton J. W. Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother. 1991 May;35(5):1008–1010. doi: 10.1128/aac.35.5.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Haag R., Lexa P., Werkhäuser I. Artifacts in dilution pharmacokinetic models caused by adherent bacteria. Antimicrob Agents Chemother. 1986 May;29(5):765–768. doi: 10.1128/aac.29.5.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kadurugamuwa J. L., Anwar H., Brown M. R., Shand G. H., Ward K. H. Media for study of growth kinetics and envelope properties of iron-deprived bacteria. J Clin Microbiol. 1987 May;25(5):849–855. doi: 10.1128/jcm.25.5.849-855.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Klastersky J., Cappel R., Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother. 1972 Dec;2(6):470–475. doi: 10.1128/aac.2.6.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lam J., Chan R., Lam K., Costerton J. W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun. 1980 May;28(2):546–556. doi: 10.1128/iai.28.2.546-556.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. May T. B., Shinabarger D., Maharaj R., Kato J., Chu L., DeVault J. D., Roychoudhury S., Zielinski N. A., Berry A., Rothmel R. K. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev. 1991 Apr;4(2):191–206. doi: 10.1128/cmr.4.2.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nicas T. I., Iglewski B. H. The contribution of exoproducts to virulence of Pseudomonas aeruginosa. Can J Microbiol. 1985 Apr;31(4):387–392. doi: 10.1139/m85-074. [DOI] [PubMed] [Google Scholar]
  14. Nichols W. W., Evans M. J., Slack M. P., Walmsley H. L. The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J Gen Microbiol. 1989 May;135(5):1291–1303. doi: 10.1099/00221287-135-5-1291. [DOI] [PubMed] [Google Scholar]
  15. Nickel J. C., Ruseska I., Wright J. B., Costerton J. W. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother. 1985 Apr;27(4):619–624. doi: 10.1128/aac.27.4.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pier G. B. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis. 1985 Apr;151(4):575–580. doi: 10.1093/infdis/151.4.575. [DOI] [PubMed] [Google Scholar]
  17. Slack M. P., Nichols W. W. Antibiotic penetration through bacterial capsules and exopolysaccharides. J Antimicrob Chemother. 1982 Nov;10(5):368–372. doi: 10.1093/jac/10.5.368. [DOI] [PubMed] [Google Scholar]
  18. Vasil M. L. Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology. J Pediatr. 1986 May;108(5 Pt 2):800–805. doi: 10.1016/s0022-3476(86)80748-x. [DOI] [PubMed] [Google Scholar]
  19. van Loosdrecht M. C., Lyklema J., Norde W., Zehnder A. J. Influence of interfaces on microbial activity. Microbiol Rev. 1990 Mar;54(1):75–87. doi: 10.1128/mr.54.1.75-87.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES